Researchers have found that a brain marker measured using electroencephalography (EEG) could predict what kind of antidepressant patients are most likely to respond to. This could provide an early indicator to determine what drugs patients should be given - this is currently guided by trial and error.
The 375-BRITE (Biomarkers for Rapid Identification of Treatment Effectiveness) trial tested Aspect Medical Systems' Antidepressant Treatment Response (ATR) marker in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?